Mechanistic rationales for targeting interleukin-17A in spondyloarthritis

Siba P Raychaudhuri, Smriti K. Raychaudhuri

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

The term spondyloarthritis (SpA) is used to describe a group of inflammatory autoimmune diseases, including ankylosing spondylitis and psoriatic arthritis, with common genetic risk factors and clinical features. SpA is clinically distinct from rheumatoid arthritis and typically affects the spine, sacroiliac joints, entheses, and, less commonly, peripheral joints. Although the pathogenesis of SpA is not fully understood, recent findings have identified the interleukin (IL)-17 pathway as a key mediator of disease pathogenesis. Clinical evidence for the efficacy of IL-17A inhibition by biologic agents was initially shown in patients with chronic plaque psoriasis, another autoimmune disease mediated by the IL-17 pathway. Subsequently, similar positive efficacy for inhibition of IL-17A was seen in patients with ankylosing spondylitis and psoriatic arthritis. Inhibition of IL-17A may also improve cardiovascular and metabolic comorbidities often found in patients with SpA because studies have linked these disorders to the IL-17 pathway. In this review, we will examine key preclinical studies that demonstrated the mechanistic role of IL-17A in the development SpA and discuss how these observations were translated into clinical practice.

Original languageEnglish (US)
Article number51
JournalArthritis Research and Therapy
Volume19
Issue number1
DOIs
StatePublished - Mar 8 2017

Fingerprint

Interleukin-17
Psoriatic Arthritis
Ankylosing Spondylitis
Autoimmune Diseases
Sacroiliac Joint
Biological Factors
Psoriasis
Comorbidity
Rheumatoid Arthritis
Spine
Joints

Keywords

  • Ankylosing spondylitis
  • Clinical practice
  • IL-17A inhibition
  • Interleukin-17
  • Preclinical studies
  • Psoriatic arthritis
  • Review
  • Spondyloarthritis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

Mechanistic rationales for targeting interleukin-17A in spondyloarthritis. / Raychaudhuri, Siba P; Raychaudhuri, Smriti K.

In: Arthritis Research and Therapy, Vol. 19, No. 1, 51, 08.03.2017.

Research output: Contribution to journalReview article

@article{878835736a1347d590e615e492bbe803,
title = "Mechanistic rationales for targeting interleukin-17A in spondyloarthritis",
abstract = "The term spondyloarthritis (SpA) is used to describe a group of inflammatory autoimmune diseases, including ankylosing spondylitis and psoriatic arthritis, with common genetic risk factors and clinical features. SpA is clinically distinct from rheumatoid arthritis and typically affects the spine, sacroiliac joints, entheses, and, less commonly, peripheral joints. Although the pathogenesis of SpA is not fully understood, recent findings have identified the interleukin (IL)-17 pathway as a key mediator of disease pathogenesis. Clinical evidence for the efficacy of IL-17A inhibition by biologic agents was initially shown in patients with chronic plaque psoriasis, another autoimmune disease mediated by the IL-17 pathway. Subsequently, similar positive efficacy for inhibition of IL-17A was seen in patients with ankylosing spondylitis and psoriatic arthritis. Inhibition of IL-17A may also improve cardiovascular and metabolic comorbidities often found in patients with SpA because studies have linked these disorders to the IL-17 pathway. In this review, we will examine key preclinical studies that demonstrated the mechanistic role of IL-17A in the development SpA and discuss how these observations were translated into clinical practice.",
keywords = "Ankylosing spondylitis, Clinical practice, IL-17A inhibition, Interleukin-17, Preclinical studies, Psoriatic arthritis, Review, Spondyloarthritis",
author = "Raychaudhuri, {Siba P} and Raychaudhuri, {Smriti K.}",
year = "2017",
month = "3",
day = "8",
doi = "10.1186/s13075-017-1249-5",
language = "English (US)",
volume = "19",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Mechanistic rationales for targeting interleukin-17A in spondyloarthritis

AU - Raychaudhuri, Siba P

AU - Raychaudhuri, Smriti K.

PY - 2017/3/8

Y1 - 2017/3/8

N2 - The term spondyloarthritis (SpA) is used to describe a group of inflammatory autoimmune diseases, including ankylosing spondylitis and psoriatic arthritis, with common genetic risk factors and clinical features. SpA is clinically distinct from rheumatoid arthritis and typically affects the spine, sacroiliac joints, entheses, and, less commonly, peripheral joints. Although the pathogenesis of SpA is not fully understood, recent findings have identified the interleukin (IL)-17 pathway as a key mediator of disease pathogenesis. Clinical evidence for the efficacy of IL-17A inhibition by biologic agents was initially shown in patients with chronic plaque psoriasis, another autoimmune disease mediated by the IL-17 pathway. Subsequently, similar positive efficacy for inhibition of IL-17A was seen in patients with ankylosing spondylitis and psoriatic arthritis. Inhibition of IL-17A may also improve cardiovascular and metabolic comorbidities often found in patients with SpA because studies have linked these disorders to the IL-17 pathway. In this review, we will examine key preclinical studies that demonstrated the mechanistic role of IL-17A in the development SpA and discuss how these observations were translated into clinical practice.

AB - The term spondyloarthritis (SpA) is used to describe a group of inflammatory autoimmune diseases, including ankylosing spondylitis and psoriatic arthritis, with common genetic risk factors and clinical features. SpA is clinically distinct from rheumatoid arthritis and typically affects the spine, sacroiliac joints, entheses, and, less commonly, peripheral joints. Although the pathogenesis of SpA is not fully understood, recent findings have identified the interleukin (IL)-17 pathway as a key mediator of disease pathogenesis. Clinical evidence for the efficacy of IL-17A inhibition by biologic agents was initially shown in patients with chronic plaque psoriasis, another autoimmune disease mediated by the IL-17 pathway. Subsequently, similar positive efficacy for inhibition of IL-17A was seen in patients with ankylosing spondylitis and psoriatic arthritis. Inhibition of IL-17A may also improve cardiovascular and metabolic comorbidities often found in patients with SpA because studies have linked these disorders to the IL-17 pathway. In this review, we will examine key preclinical studies that demonstrated the mechanistic role of IL-17A in the development SpA and discuss how these observations were translated into clinical practice.

KW - Ankylosing spondylitis

KW - Clinical practice

KW - IL-17A inhibition

KW - Interleukin-17

KW - Preclinical studies

KW - Psoriatic arthritis

KW - Review

KW - Spondyloarthritis

UR - http://www.scopus.com/inward/record.url?scp=85014734278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014734278&partnerID=8YFLogxK

U2 - 10.1186/s13075-017-1249-5

DO - 10.1186/s13075-017-1249-5

M3 - Review article

C2 - 28270233

AN - SCOPUS:85014734278

VL - 19

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 1

M1 - 51

ER -